Etiology of valvular heart disease - Genetic and developmental origins

Circulation Journal

Volumn 78, Issue 8, 2014, Pages 1801-1807

  Lincoln, Joy ^a   Garg, Vidu ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Aortic valve calcification; Bicuspid aortic valve; Heart valve development; Mitral valve prolapse; Valvular heart disease

Indexed keywords

EMBRYOLOGY; GENETICS; HEART VALVE; HEART VALVE DISEASES; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

HEART VALVE DISEASES; HEART VALVES; HUMANS; SIGNAL TRANSDUCTION;

EID: 84904965491     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0510     Document Type: Review

References (77)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Executive Summary: Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation 2013; 127: 143-152.
2. d'Arcy JL, Prendergast BD, Chambers JB, Ray SG, Bridgewater B. Valvular heart disease: The next cardiac epidemic. Heart 2011; 97: 91-93.
3. Le Gloan L, Mercier LA, Dore A, Marcotte F, Ibrahim R, Mongeon FP, et al. Recent advances in adult congenital heart disease. Circ J 2011; 75: 2287-2295.
4. Itagaki S, Adams DH, Anyanwu AC. Triggers for surgical referral in degenerative mitral valve regurgitation. Circ J 2013; 77: 28-34.
5. Maeda K, Kuratani T, Mizote I, Shimamura K, Takeda Y, Torikai K, et al. Early experiences of transcatheter aortic valve replacement in Japan. Circ J 2013; 77: 359-362.
6. Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, et al. Calcific aortic valve disease: Not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation 2011; 124: 1783-1791.
7. Hinton RB Jr, Lincoln J, Deutsch GH, Osinska H, Manning PB, Benson DW, et al. Extracellular matrix remodeling and organization in developing and diseased aortic valves. Circ Res 2006; 98: 1431-1438.
8. Tao G, Kotick JD, Lincoln J. Heart valve development, maintenance, and disease: The role of endothelial cells. Curr Top Dev Biol 2012; 100: 203-232.
9. Lincoln J, Florer JB, Deutsch GH, Wenstrup RJ, Yutzey KE. ColVa1 and ColXIa1 are required for myocardial morphogenesis and heart valve development. Dev Dyn 2006; 235: 3295-3305.
10. Grande-Allen KJ, Liao J. The heterogeneous biomechanics and mechanobiology of the mitral valve: Implications for tissue engineering. Curr Cardiol Rep 2011; 13: 113-120.
11. Sacks MS, David Merryman W, Schmidt DE. On the biomechanics of heart valve function. J Biomech 2009; 42: 1804-1824.
12. Schoen FJ. Evolving concepts of cardiac valve dynamics. Circulation 2008; 118: 1864-1880.
13. Hinton RB, Yutzey KE. Heart valve structure and function in development and disease. Annu Rev Physiol 2011; 73: 29-46.
14. Kodo K, Yamagishi H. A decade of advances in the molecular embryology and genetics underlying congenital heart defects. Circ J 2011; 75: 2296-2304.
15. Person AD, Klewer SE, Runyan RB. Cell biology of cardiac cushion development. Int Rev Cytol 2005; 243: 287-335.
16. deLange FJ, Moorman AFM, Anderson RH, Manner J, Soufan AT, deGier-deVries C, et al. Lineage and morphogenetic analysis of the cardiac valves. Circ Res 2004; 95: 645-654.
17. Lincoln J, Alfieri CM, Yutzey KE. Development of heart valve leaflets and supporting apparatus in chicken and mouse embryos. Dev Dyn 2004; 230: 239-250.
18. Wessels A, van den Hoff MJ, Adamo RF, Phelps AL, Lockhart MM, Sauls K, et al. Epicardially derived fibroblasts preferentially contribute to the parietal leaflets of the atrioventricular valves in the murine heart. Dev Biol 2012; 366: 111-124.
19. Jiang X, Rowitch DH, Soriano P, McMahon AP, Sucov HM. Fate of the mammalian cardiac neural crest. Development 2000; 127: 1607-1616.
20. Kruithof BP, Duim SN, Moerkamp AT, Goumans MJ. TGFβ and BMP signaling in cardiac cushion formation: Lessons from mice and chicken. Differentation 2012; 84: 89-102.
21. Yamagishi T, Ando K, Nakamura H. Roles of TGFβ and BMP during valvulo-septal endocardial cushion formation. Anat Sci Int 2009; 84: 77-87.
22. Azhar M, Schultz JJ, Grupp I, Dorn GW, Meneton P, Molin DG, et al. Transforming growth factor beta in cardiovascular development and function. Cytokine Growth Factor Rev 2003; 14: 391-407.
23. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, et al. The transcription factor snail controls epithelialmesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2: 76-83.
24. Niessen K, Fu Y, Chang L, Hoodless PA, McFadden D, Karsan A. Slug is a direct Notch target required for initiation of cardiac cushion cellularization. J Cell Biol 2008; 182: 315-325.
25. Tao G, Levay AK, Gridley T, Lincoln J. Mmp15 is a direct target of Snai1 during endothelial to mesenchymal transformation and endocardial cushion development. Dev Biol 2011; 359: 209-221.
26. Combs MD, Yutzey KE. Heart valve development: Regulatory networks in development and disease. Circ Res 2009; 105: 408-421.
27. Liebner S, Cattelino A, Gallini R, Rudini N, Iurlaro M, Piccolo S, et al. β-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol 2004; 166: 359-367.
28. Hurlstone AF, Haramis AP, Wienholds E, Begthel H, Korving J, Van Eeden F, et al. The Wnt/beta-catenin pathway regulates cardiac valve formation. Nature 2003; 425: 633-637.
29. Person AD, Garriock RJ, Krieg PA, Runyan RB, Klewer SE. Frzb modulates Wnt-9a-mediated beta-catenin signaling during avian atrioventricular cardiac cushion development. Dev Biol 2005; 278: 35-48.
30. de la Pompa JL, Epstein JA. Coordinating tissue interactions: Notch signaling in cardiac development and disease. Dev Cell 2012; 22: 244-254.
31. Luna-Zurita L, Prados B, Grego-Bessa J, Luxan G, del Monte G, Benguria A, et al. Integration of a Notch-dependent mesenchymal gene program and Bmp2-driven cell invasiveness regulates murine cardiac valve formation. J Clin Invest 2010; 120: 3493-3507.
32. Venkatesh DA, Park KS, Harrington A, Miceli-Libby L, Yoon JK, Liaw L. Cardiovascular and hematopoietic defects associated with Notch1 activation in embryonic Tie2-expressing populations. Circ Res 2008; 103: 423-431.
33. Niessen K, Karsan A. Notch signaling in cardiac development. Circ Res 2008; 102: 1169-1181.
34. Kokubo H, Tomita-Miyagawa S, Hamada Y, Saga Y. Hesr1 and Hesr2 regulate atrioventricular boundary formation in the developing heart through the repression of Tbx2. Development 2007; 134: 747-755.
35. Rutenberg JB, Fischer A, Jia H, Gessler M, Zhong TP, Mercola M. Developmental patterning of the cardiac atrioventricular canal by Notch and Hairy-related transcription factors. Development 2006; 133: 4381-4390.
36. Dor Y, Camenisch TD, Itin A, Fishman GI, McDonald JA, Carmeliet P, et al. A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects. Development 2001; 128: 1531-1538.
37. Combs MD, Yutzey KE. VEGF and RANKL regulation of NFATc1 in heart valve development. Circ Res 2009; 105: 565-574.
38. Stankunas K, Ma GK, Kuhnert FJ, Kuo CJ, Chang CP. VEGF signaling has distinct spatiotemporal roles during heart valve development. Dev Biol 2010; 347: 325-336.
39. Wu B, Wang Y, Lui W, Langworthy M, Tompkins KL, Hatzopoulos AK, et al. Nfatc1 coordinates valve endocardial cell lineage development required for heart valve formation. Circ Res 2011; 109: 183-192.
40. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 2001; 104: 2525-2532.
41. Inai K, Burnside JL, Hoffman S, Toole BP, Sugi Y. BMP-2 induces versican and hyaluronan that contribute to post-EMT AV cushion cell migration. PLoS One 2013; 8: e77593, doi:10.1371/journal. pone.0077593.
42. Lincoln J, Kist R, Scherer G, Yutzey KE. Sox9 is required for precursor cell expansion and extracellular matrix organization during mouse heart valve development. Dev Biol 2007; 305: 120-132.
43. Barnette DN, Hulin A, Ahmed AS, Colige AC, Azhar M, Lincoln J. Tgfbeta-Smad and MAPK signaling mediate scleraxis and proteoglycan expression in heart valves. J Mol Cell Cardiol 2013; 65: 137-146.
44. Lahaye S, Lincoln J, Garg V. Genetics of valvular heart disease. Curr Cardiol Rep 2014; 16: 487.
45. McBride KL, Garg V. Heredity of bicuspid aortic valve: Is family screening indicated? Heart 2011; 97: 1193-1195.
46. Garg V. Molecular genetics of aortic valve disease. Curr Opin Cardiol 2006; 21: 180-184.
47. Fernandez B, Duran AC, Fernandez-Gallego T, Fernandez MC, Such M, Arque JM, et al. Bicuspid aortic valves with different spatial orientations of the leaflets are distinct etiological entities. J Am Coll Cardiol 2009; 54: 2312-2318.
48. Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J Med 2014; 370: 1920-1929.
49. McBride KL, Riley MF, Zender GA, Fitzgerald-Butt SM, Towbin JA, Belmont JW, et al. NOTCH1 mutations in individuals with left ventricular outflow tract malformations reduce ligand-induced signaling. Hum Mol Genet 2008; 17: 2886-2893.
50. Foffa I, Ait Ali L, Panesi P, Mariani M, Festa P, Botto N, et al. Sequencing of NOTCH1, GATA5, TGFBR1 and TGFBR2 genes in familial cases of bicuspid aortic valve. BMC Med Genet 2013; 14: 44.
51. Bosse K, Hans CP, Zhao N, Koenig SN, Huang N, Guggilam A, et al. Endothelial nitric oxide signaling regulates Notch1 in aortic valve disease. J Mol Cell Cardiol 2013; 60: 27-35.
52. Laforest B, Andelfinger G, Nemer M. Loss of Gata5 in mice leads to bicuspid aortic valve. J Clin Invest 2011; 121: 2876-2887.
53. Padang R, Bagnall RD, Richmond DR, Bannon PG, Semsarian C. Rare non-synonymous variations in the transcriptional activation domains of GATA5 in bicuspid aortic valve disease. J Mol Cell Cardiol 2012; 53: 277-281.
54. Bonachea EM, Chang SW, Zender G, LaHaye S, Fitzgerald-Butt S, McBride KL, et al. Rare GATA5 sequence variants identified in individuals with bicuspid aortic valve. Pediatr Res 2014 May 5, doi:10.1038/pr.2014.67.
55. Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999; 341: 1-7.
56. Gupta V, Barzilla JE, Mendez JS, Stephens EH, Lee EL, Collard CD, et al. Abundance and localization of proteoglycans and hyaluronan within normal and myxomatous mitral valves. Cardiovasc Pathol 2009; 18: 191-197.
57. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991; 352: 337-339.
58. Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004; 114: 1586-1592.
59. Judge DP, Markwald RR, Hagege AA, Levine RA. Translational research on the mitral valve: From developmental mechanisms to new therapies. J Cardiovasc Transl Res 2011; 4: 699-701.
60. Kyndt F, Gueffet JP, Probst V, Jaafar P, Legendre A, Le Bouffant F, et al. Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy. Circulation 2007; 115: 40-49.
61. Lardeux A, Kyndt F, Lecointe S, Marec HL, Merot J, Schott JJ, et al. Filamin-a-related myxomatous mitral valve dystrophy: Genetic, echocardiographic and functional aspects. J Cardiovasc Transl Res 2011; 4: 748-756.
62. Sauls K, de Vlaming A, Harris BS, Williams K, Wessels A, Levine RA, et al. Developmental basis for filamin-A-associated myxomatous mitral valve disease. Cardiovasc Res 2012; 96: 109-119.
63. Probst V, Le Scouarnec S, Legendre A, Jousseaume V, Jaafar P, Nguyen JM, et al. Familial aggregation of calcific aortic valve stenosis in the western part of France. Circulation 2006; 113: 856-860.
64. Bella JN, Tang W, Kraja A, Rao DC, Hunt SC, Miller MB, et al. Genome-wide linkage mapping for valve calcification susceptibility loci in hypertensive sibships: The Hypertension Genetic Epidemiology Network Study. Hypertension 2007; 49: 453-460.
65. Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013; 368: 503-512.
66. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, et al. Mutations in NOTCH1 cause aortic valve disease. Nature 2005; 437: 270-274.
67. Hofmann JJ, Briot A, Enciso J, Zovein AC, Ren S, Zhang ZW, et al. Endothelial deletion of murine Jag1 leads to valve calcification and congenital heart defects associated with Alagille syndrome. Development 2012; 139: 4449-4460.
68. Kokubo H, Miyagawa-Tomita S, Nakashima Y, Kume T, Yoshizumi M, Nakanishi T, et al. Hesr2 knockout mice develop aortic valve disease with advancing age. Arterioscl Thromb Vasc Biol 2013; 33: e84-e92, doi:10.1161/ATVBAHA.112.300573.
69. Nus M, MacGrogan D, Martinez-Poveda B, Benito Y, Casanova JC, Fernandez-Aviles F, et al. Diet-induced aortic valve disease in mice haploinsufficient for the Notch pathway effector RBPJK/CSL. Arterioscler Thromb Vasc Biol 2011; 31: 1580-1588.
70. Acharya A, Hans CP, Koenig SN, Nichols HA, Galindo CL, Garner HR, et al. Inhibitory role of Notch1 in calcific aortic valve disease. PLoS One 2011; 6: e27743, doi:10.1371/journal.pone.0027743.
71. Peacock JD, Levay AK, Gillaspie DB, Tao G, Lincoln J. Reduced sox9 function promotes heart valve calcification phenotypes in vivo. Circ Res 2010; 106: 712-719.
72. Peacock JD, Huk DJ, Ediriweera HN, Lincoln J. Sox9 transcriptionally represses Spp1 to prevent matrix mineralization in maturing heart valves and chondrocytes. PLoS One 2011; 6: e26769, doi:10.1371/ journal.pone.0026769.
73. Wirrig EE, Hinton RB, Yutzey KE. Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves. J Mol Cell Cardiol 2011; 50: 561-569.
74. Alexopoulos A, Bravou V, Peroukides S, Kaklamanis L, Varakis J, Alexopoulos D, et al. Bone regulatory factors NFATc1 and Osterix in human calcific aortic valves. Int J Cardiol 2010; 139: 142-149.
75. Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptormediated bone formation. J Am Coll Cardiol 2006; 47: 1707-1712.
76. Morita H. Human genomics in cardiovascular medicine: Implications and perspectives. Circ J 2013; 77: 876-885.
77. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys B, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312: 117-121.